Oral Biologics & Biosimilars Global Market Report 2026
상품코드:1957539
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
경구 생물학적 제제 및 바이오시밀러 시장 규모는 최근 급격하게 확대되고 있습니다. 2025년 93억 7,000만 달러에서 2026년에는 112억 8,000만 달러에 이르고, CAGR 20.3%의 성장이 전망되고 있습니다. 지금까지의 성장 요인으로는 경구용 바이오의약품공급 제한, 생물학적 제제의 높은 비용, 주사제에 대한 의존도, 만성질환 증가, 병원 및 소매 약국 네트워크의 확대 등을 꼽을 수 있습니다.
경구 바이오의약품 및 바이오시밀러 시장 규모는 향후 몇 년간 급격한 성장이 전망됩니다. 2030년에는 246억 9,000만 달러에 이르고, CAGR은 21.6%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 바이오시밀러 및 병용요법 개발, 경구 생물학적 제제 파이프라인 확대, 경구용 의약품에 대한 환자 선호도 증가, 디지털 복약관리 도구 도입 증가, 정부 지원 및 상환 정책 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 만성질환에 대한 경구용 바이오의약품 및 바이오시밀러의 채택 증가, 당뇨병, 관절염, 암에 대한 표적치료제의 성장, 단일클론항체 기반 경구용 치료제 개발 확대, 병원, 소매 및 온라인 약국 유통 채널 확대, 환자 순응도 및 맞춤형 치료 계획에 대한 집중 등이 있습니다. 환자 순응도 및 맞춤형 치료계획에 대한 집중 등을 들 수 있습니다.
만성질환의 유병률 증가는 향후 경구용 바이오의약품 및 바이오시밀러 시장을 견인할 것으로 예측됩니다. 만성질환이란 당뇨병, 심장질환, 폐질환 등 서서히 진행되는 지속적인 건강상태를 말합니다. 이러한 급격한 증가는 주로 운동 부족 생활 방식에 기인하며, 장기간의 운동 부족은 비만, 심혈관 질환, 2형 당뇨병, 특정 암의 위험을 증가시킵니다. 경구용 바이오의약품과 바이오시밀러는 지속적인 만성질환 치료에서 편리하고 경제적이며 환자 친화적인 대안을 제공함으로써 이 분야를 발전시킬 것입니다. 예를 들어, 2023년 1월 미국 질병예방통제센터(CDC)가 발표한 자료에 따르면, 같은 해 미국 성인의 76.4%(약 1억 9,400만 명)가 적어도 한 가지 이상의 만성질환을 앓고 있으며, 젊은 성인의 경우 59.5%, 중년 성인의 경우 78.4%, 노년 성인의 경우 93.0%가 만성질환을 앓고 있는 것으로 나타났습니다. 에 이르렀습니다. 따라서 만성질환 유병률 증가는 경구용 바이오의약품 및 바이오시밀러 시장의 성장을 가속하고 있습니다.
경구용 바이오의약품 및 바이오시밀러 시장의 주요 기업들은 경구용 바이오의약품의 전달 정확도 향상, 생체 이용률 향상, 주사제 대비 간편한 투여를 실현하기 위해 맞춤형 스마트 캡슐 서비스 개발을 선도하고 있습니다. 스마트 캡슐은 특수 코팅, 서방형 시스템 또는 보호제를 채택하여 바이오 의약품을 장내 분해로부터 보호하고 장내 흡수를 정확하게 제어함으로써 바늘을 사용하지 않는 투여 경로와 높은 복약 순응도를 제공합니다. 예를 들어, 2024년 12월 스위스에 본사를 둔 위탁개발제조기관(CDMO)인 론자 그룹 AG는 경구용 바이오 의약품을 위한 맞춤형 스마트 캡슐 개발 서비스를 시작했습니다. 본 서비스는 바이오의약품의 안정성과 정밀한 방출을 실현하기 위한 맞춤형 제제 설계, 첨가제 선정, 캡슐 설계를 포괄하고 있습니다. 취약한 생체 분자의 흡수율을 높이면서 효능을 유지하는 구조입니다. 주요 특징은 구상 단계부터 전임상시험까지 전주기 지원, 다제 대응성(단백질, 펩타이드, 핵산), 확장 가능한 생산 체계입니다. 적용 범위는 경구용 단일클론항체, 펩타이드, 백신 등입니다. 환자 편의성 향상, 주사 의존도 감소, 복약 순응도 향상, 경구용 치료제 개발 일정 단축 등의 이점이 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Biologics are drugs derived from living cells using highly sophisticated technologies, whereas biosimilars are developed to act similarly to biologics but are not exact replicas. Oral biologics and biosimilars include biologic and biosimilar drugs administered orally for the targeted treatment of conditions such as Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious diseases. They are also used to manage chronic illnesses like diabetes, arthritis, and cancer.
The main therapy types of oral biologics and biosimilar lymphocytes are modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors, immunostimulants, GPCR modulators, and others. Interleukin inhibitors are immunosuppressive drugs that block the activity of interleukins. These therapies address diseases including asthma, Crohn's disease, cancer, infectious diseases, autoimmune disorders, and others, using molecular types such as vaccines, proteins and peptides, monoclonal antibodies, and additional therapeutics. They are distributed through hospital pharmacies, retail pharmacies, and online channels.
Tariffs have impacted the oral biologics and biosimilars market by increasing the cost of imported active pharmaceutical ingredients, proteins, and peptides used in oral biologic formulations. Segments such as monoclonal antibodies and protein-based therapies are most affected, particularly in North America and Europe where imports dominate. This has led to higher treatment costs and potential delays in product availability. On the positive side, tariffs have encouraged local manufacturing, innovation in cost-effective oral formulations, and diversification of the supply chain.
The oral biologics & biosimilars market research report is one of a series of new reports from The Business Research Company that provides oral biologics & biosimilars market statistics, including oral biologics & biosimilars industry global market size, regional shares, competitors with a oral biologics & biosimilars market share, detailed oral biologics & biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics & biosimilars industry. This oral biologics & biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oral biologics & biosimilars market size has grown exponentially in recent years. It will grow from $9.37 billion in 2025 to $11.28 billion in 2026 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to limited availability of oral biologics, high cost of biologic therapies, reliance on injectable formulations, increasing prevalence of chronic diseases, growing hospital and retail pharmacy networks.
The oral biologics & biosimilars market size is expected to see exponential growth in the next few years. It will grow to $24.69 billion in 2030 at a compound annual growth rate (CAGR) of 21.6%. The growth in the forecast period can be attributed to development of biosimilars and combination therapies, expansion of oral biologics pipelines, increasing patient preference for oral medications, rising adoption of digital adherence tools, growing government support and reimbursement policies. Major trends in the forecast period include rising adoption of oral biologics and biosimilars for chronic diseases, growth in targeted therapies for diabetes, arthritis, and cancer, increasing development of monoclonal antibody-based oral treatments, expansion of hospital, retail, and online pharmacy distribution channels, focus on patient adherence and personalized treatment plans.
The mounting prevalence of chronic diseases is poised to boost the oral biologics and biosimilars market ahead. Chronic diseases are persistent health conditions that develop gradually, including diabetes, heart disorders, and lung issues. Their surge largely stems from inactive lifestyles, where extended lack of movement raises risks of obesity, cardiovascular problems, type 2 diabetes, and select cancers. Oral biologics and biosimilars advance this area by delivering convenient, economical, patient-friendly options for ongoing chronic care. For instance, in January 2023, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported 76.4% of U.S. adults-about 194 million-had at least one chronic condition that year, with rates hitting 59.5% in young adults, 78.4% in midlife adults, and 93.0% in older adults. Therefore, the rising prevalence of chronic diseases is driving the growth of the oral biologics and biosimilar market.
Prominent companies in the oral biologics & biosimilars market are pioneering tailored smart capsule services to refine oral biologic delivery, lift bioavailability, and offer easier dosing over injections. Smart capsules employ specialized coatings, timed-release systems, or shielding agents to protect biologics from gut breakdown and pinpoint intestinal uptake, presenting a needle-free path with better compliance. For instance, in December 2024, Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), rolled out a custom smart capsule development service for oral biologics. It covers bespoke formulation crafting, excipient picking, and capsule design for biologic stability and precise release; it works by boosting fragile biomolecule absorption while preserving potency; highlights feature full-cycle aid from idea to preclinicals, multi-modality fit (proteins, peptides, nucleic acids), and scalable production; uses include oral monoclonal antibodies, peptides, and vaccines; advantages span patient ease, less injection dependence, stronger adherence, and quicker timelines for oral therapies.
In September 2023, Biocon Limited, an India-based pharmaceutical company, acquired Eywa Pharma Inc. for $7.7 million. The acquisition additionally enables businesses to diversify their manufacturing infrastructure, ensuring supply continuity and providing oral solid dosage capacities for new products ahead of schedule. Eywa Pharma Inc. is a US-based pharmaceutical company that specializes in oral biologics and biosimilars.
Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme
North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the oral biologics & biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The oral biologics and biosimilar market consists of sales of receptor modulators, biological agents, and biosimilar lymphocytes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oral Biologics & Biosimilars Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses oral biologics & biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oral biologics & biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral biologics & biosimilars market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Therapy: Lymphocyte Modulators; Immunostimulants; GPCR Modulators; Other Therapies
2) By Disease: Diabetes; Arthritis and Crohn's Disease; Cancer; Infectious Disease; Other Autoimmune Disease; Other Diseases
3) By Molecule Type: Vaccines; Proteins and Peptides; Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Adoption Of Oral Biologics And Biosimilars For Chronic Diseases
4.2.2 Growth In Targeted Therapies For Diabetes, Arthritis, And Cancer
4.2.3 Increasing Development Of Monoclonal Antibody-Based Oral Treatments
4.2.4 Expansion Of Hospital, Retail, And Online Pharmacy Distribution Channels
4.2.5 Focus On Patient Adherence And Personalized Treatment Plans
5. Oral Biologics & Biosimilars Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Retail Pharmacies
5.3 Online Pharmacies
5.4 Specialty Clinics
5.5 Biotechnology And Pharmaceutical Companies
6. Oral Biologics & Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Oral Biologics & Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Oral Biologics & Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Oral Biologics & Biosimilars Market Size, Comparisons And Growth Rate Analysis
7.3. Global Oral Biologics & Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Oral Biologics & Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Oral Biologics & Biosimilars Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.6. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Immunostimulants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of GPCR Modulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Agonists, Antagonists, Biased Ligands
9.8. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Oral Biologics & Biosimilars Market
12.1. China Oral Biologics & Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Oral Biologics & Biosimilars Market
13.1. India Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Oral Biologics & Biosimilars Market
14.1. Japan Oral Biologics & Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Oral Biologics & Biosimilars Market
15.1. Australia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Oral Biologics & Biosimilars Market
16.1. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Oral Biologics & Biosimilars Market
17.1. South Korea Oral Biologics & Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Oral Biologics & Biosimilars Market
19.1. South East Asia Oral Biologics & Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Oral Biologics & Biosimilars Market
20.1. Western Europe Oral Biologics & Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Oral Biologics & Biosimilars Market
21.1. UK Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Oral Biologics & Biosimilars Market
22.1. Germany Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Oral Biologics & Biosimilars Market
23.1. France Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Oral Biologics & Biosimilars Market
24.1. Italy Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Oral Biologics & Biosimilars Market
25.1. Spain Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Oral Biologics & Biosimilars Market
26.1. Eastern Europe Oral Biologics & Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Oral Biologics & Biosimilars Market
27.1. Russia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Oral Biologics & Biosimilars Market
28.1. North America Oral Biologics & Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Oral Biologics & Biosimilars Market
29.1. USA Oral Biologics & Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Oral Biologics & Biosimilars Market
31.1. South America Oral Biologics & Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Oral Biologics & Biosimilars Market
32.1. Brazil Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Oral Biologics & Biosimilars Market
33.1. Middle East Oral Biologics & Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Oral Biologics & Biosimilars Market
34.1. Africa Oral Biologics & Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Oral Biologics & Biosimilars Market Regulatory and Investment Landscape
36. Oral Biologics & Biosimilars Market Competitive Landscape And Company Profiles
